Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study
BMC Cancer 2013, 13:136 doi:10.1186/1471-2407-13-136
This article is currently available as a provisional PDF. Reprints are produced from the final PDF, which is normally produced within 3 weeks.
Please complete the following form to register your interest in ordering reprints of this article. BioMed Central will contact you by email when the final PDF is available with details of how to obtain a quotation and place an order.
Fields marked * are required